So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

Looking for the best biotech penny stocks? The most important innovation of the 1990s was the internet — today, it would be a vaccine for COVID-19. If these times have anything to say about it ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

Join biotech commentators Daphne Zohar, Josh Schimmer, and Brad Loncar for a weekly discussion of all things biotech. From emerging trends and investment opportunities to the challenges facing the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Presidio Property Trust, Inc. 9.375 RED PFD D SEC Filing - Annual Report (10-K) March 31, 2025 SEC Filings Mon, Mar. 31 Presidio Property Trust 9.375% Preferred Series D declares $0.1953 dividend ...

The much-anticipated second annual edition of the Biotechnology Show continues to attract industry giants, creating a powerful platform for innovation, collaboration, and deal-making. With an ...

Via Renewables, Inc. 8.75% PFD SER A SEC Filing - Quarterly Report (10-Q) August 01, 2024 SEC Filings Thu, Aug. 01, 2024 Via Renewables 8.75% Preferred Series A declares $0.7588 dividend ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This fund holds a portfolio of 75-125 biotechnology stocks, balanced between established large-cap names and smaller companies with more growth potential but also more risk. The managers aim to ...

The Fund seeks capital appreciation by investing at least 80% of its assets in equity securities of firms engaged in research, development, distribution, and manufacture of various biotech ...